4588 Oncolys BioPharma Inc.オンコリスバイオファーマTSE Growth / Pharmaceuticals
0 posts
Oncolys BioPharma Inc. stock fell on Nov 19: what happened
It closed at ¥7,070 on Nov 19 (−¥470, −6.23%), ranking #47 among the top losers of all stocks on the Tokyo Stock Exchange.
No disclosures were found for this stock around that day. Share what you know in the posts below.
Changes are calculated from the closing prices this site collects daily; limit-up/down is an estimate based on the daily price limit. Please make your own investment decisions.
Oncolys BioPharma Inc. (4588) at a glance
Prices are from Yahoo! Finance and may be delayed. Always check the latest price before trading.
Oncolys BioPharma Inc. (4588) Stock Price History
Oncolys BioPharma Inc. closed at ¥6,940 on Nov 20, 2026, +33.7% over 1 month, +582.4% over 1 year.
If you had invested ¥100,000 1 month ago, it would be worth ¥133,719 today (+33.7%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −11.9%, while this stock moved +33.7%.
Last 10 Trading Days
| Date | Close | Change | % Change |
|---|---|---|---|
| Nov 20 (Fri) | ¥6,940 | −130 | −1.84% |
| Nov 19 (Thu) | ¥7,070 | −470 | −6.23% |
| Nov 18 (Wed) | ¥7,540 | −80 | −1.05% |
| Nov 17 (Tue) | ¥7,620 | −460 | −5.69% |
| Nov 16 (Mon) | ¥8,080 | −330 | −3.92% |
| Nov 13 (Fri) | ¥8,410 | +740 | +9.65% |
| Nov 12 (Thu) | ¥7,670 | −230 | −2.91% |
| Nov 11 (Wed) | ¥7,900 | +390 | +5.19% |
| Nov 10 (Tue) | ¥7,510 | +410 | +5.77% |
| Nov 9 (Mon) | ¥7,100 | −300 | −4.05% |
If you had invested ¥100,000 3 months ago, it would be worth ¥186,559 today (+86.6%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −14.8%, while this stock moved +86.6%.
Last 10 Trading Days
| Date | Close | Change | % Change |
|---|---|---|---|
| Nov 20 (Fri) | ¥6,940 | −130 | −1.84% |
| Nov 19 (Thu) | ¥7,070 | −470 | −6.23% |
| Nov 18 (Wed) | ¥7,540 | −80 | −1.05% |
| Nov 17 (Tue) | ¥7,620 | −460 | −5.69% |
| Nov 16 (Mon) | ¥8,080 | −330 | −3.92% |
| Nov 13 (Fri) | ¥8,410 | +740 | +9.65% |
| Nov 12 (Thu) | ¥7,670 | −230 | −2.91% |
| Nov 11 (Wed) | ¥7,900 | +390 | +5.19% |
| Nov 10 (Tue) | ¥7,510 | +410 | +5.77% |
| Nov 9 (Mon) | ¥7,100 | −300 | −4.05% |
If you had invested ¥100,000 6 months ago, it would be worth ¥340,029 today (+240.0%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −5.6%, while this stock moved +240.0%.
Monthly Closes
| Month | Month-End Close | Monthly % |
|---|---|---|
| Nov 2026 | ¥6,940 | −8.2% |
| Oct 2026 | ¥7,560 | +27.5% |
| Sep 2026 | ¥5,930 | +27.5% |
| Aug 2026 | ¥4,650 | +74.5% |
| Jul 2026 | ¥2,665 | −9.9% |
| Jun 2026 | ¥2,957 | +6.9% |
| May 2026 | ¥2,765 | −2.0% |
If you had invested ¥100,000 1 year ago, it would be worth ¥682,399 today (+582.4%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +13.3%, while this stock moved +582.4%.
Monthly Closes
| Month | Month-End Close | Monthly % |
|---|---|---|
| Nov 2026 | ¥6,940 | −8.2% |
| Oct 2026 | ¥7,560 | +27.5% |
| Sep 2026 | ¥5,930 | +27.5% |
| Aug 2026 | ¥4,650 | +74.5% |
| Jul 2026 | ¥2,665 | −9.9% |
| Jun 2026 | ¥2,957 | +6.9% |
| May 2026 | ¥2,765 | −2.0% |
| Apr 2026 | ¥2,820 | +30.7% |
| Mar 2026 | ¥2,157 | −21.0% |
| Feb 2026 | ¥2,730 | +57.0% |
| Jan 2026 | ¥1,739 | +25.7% |
| Dec 2025 | ¥1,384 | +17.9% |
| Nov 2025 | ¥1,174 | ― |
If you had invested ¥100,000 3 years ago, it would be worth ¥1,186,325 today (+1,086.3%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +67.8%, while this stock moved +1,086.3%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥6,940 | +401.4% |
| 2025 | ¥1,384 | ― |
If you had invested ¥100,000 5 years ago, it would be worth ¥1,084,375 today (+984.4%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +96.3%, while this stock moved +984.4%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥6,940 | +401.4% |
| 2025 | ¥1,384 | ― |
If you had invested ¥100,000 in Jan 2014, it would be worth ¥222,436 today (+122.4%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +280.6%, while this stock moved +122.4%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥6,940 | +401.4% |
| 2025 | ¥1,384 | +167.2% |
| 2024 | ¥518 | −8.6% |
| 2023 | ¥567 | +7.6% |
| 2022 | ¥527 | −0.2% |
| 2021 | ¥528 | −64.9% |
| 2020 | ¥1,503 | −21.8% |
| 2019 | ¥1,923 | +86.0% |
| 2018 | ¥1,034 | +32.4% |
| 2017 | ¥781 | −27.6% |
| 2016 | ¥1,079 | +67.5% |
| 2015 | ¥644 | −17.2% |
| 2014 | ¥778 | ― |
Daily, weekly and monthly closes (Yahoo! Finance, split-adjusted, dividends excluded). "All" covers the range Yahoo provides (from Jan 2014). Please check the latest prices before trading.
Oncolys BioPharma Inc. (4588) financial indicators
PER, ROE and dividend yield are based on company forecasts, calculated from earnings reports and the closing price after each trading day.
Key features of Oncolys BioPharma Inc. (4588)
Business overview
The company is a drug discovery biotech developing oncolytic virus therapies for cancer and treatments for severe viral infections. Its main pipeline consists of the oncolytic viruses OBP-301 and OBP-702 and the antiviral OBP-2011, while OBP-601, originally developed for HIV, is being developed for intractable neurological diseases. It filed for approval of OBP-301 in Japan in December 2025 and is moving toward a model of obtaining approvals and selling drugs itself.
Summarized from the annual securities report (fiscal year ended December 2025) filed on EDINET.
Position within Pharmaceuticals (79 companies)
| PBR | 66.56x | Above the sector median of 1.86x (No. 75 from the lowest) |
|---|---|---|
| Market cap | ¥205.1 bn | No. 15 in the sector (largest first) |
Ranks among stocks in the same Tokyo Stock Exchange sector (33 sectors). PER and PBR of zero or below (losses, negative equity) are excluded and ranked from the lowest.
Price milestones
| 52-week high | ¥8,410 | 11/13 |
|---|---|---|
| 52-week low | ¥780 | 2025/12/17 |
| Current position | 80.7% | Where the low is 0% and the high is 100% (close on 11/20: ¥6,940) |
| Year to date | +401.4% | No. 1 of 77 in the sector (best first) |
| 1 year | +582.4% |
Based on closing prices (adjusted for stock splits, excluding dividends).
Kabutaro's ranking history
| Top 50 gainers | 9 times | Latest: 11/13 (No. 37) |
|---|---|---|
| Top 50 losers | 5 times | Latest: 11/19 (No. 47) |
Gainers and losers have been recorded since 9/2026.
Calculated as of 2026/11/20 17:30 JST. Updated every business day in the evening.
Recent disclosures (TDnet, in Japanese)
- 11/10 08:00腫瘍溶解ウイルス テロメライシンの新たな適応(喉頭がん・咽頭がん)での治験届提出に関するお知らせ
- 11/06 15:30譲渡制限付株式報酬としての新株式発行に関するお知らせ
- 11/06 15:302026年12月期第3四半期決算短信〔日本基準〕(非連結)
- 11/06 15:30営業外収益及び営業外費用の計上に関するお知らせ
- 10/30 15:30腫瘍溶解ウイルス テロメライシン注の新たな適応を目指した臨床試験の投与開始に関するお知らせ
- 10/08 15:30腫瘍溶解ウイルス テロメライシン注の24か月安定性試験結果のお知らせ
Filings from the past 12 months (6).
Posts
This board is shared with the Japanese and Chinese versions. Feel free to write in English, Chinese or Japanese.
No posts yet. Be the first to write something.
Write on the Oncolys BioPharma Inc. board
More Japanese stocks in English
- PLAN DO Co.,Ltd.458A
- RIBOMIC Inc.4591
- SanBio Company Limited4592
- HEALIOS K.K.4593
- BrightPath Biotherapeutics Co.,Ltd.4594
- MIZUHO MEDY CO.,LTD.4595
- Kubota Pharmaceutical Holdings Co.,Ltd.4596
- Solasia Pharma K.K.4597
- Delta-Fly Pharma,Inc.4598
- StemRIM Inc.4599
- Nomura High-yield J-REIT Index ETF459A
- BRANU Inc.460A